TScan Therapeutics Inc (TCRX)

[FACT-MASTER]

Let's go back to the latest 10-Q for a minute

https://www.sec.gov/ix?doc=/Archives/edgar/data/1783328/000095017023020087/tcrx-20230331.htm

As of May 5, 2023, the registrant had 19,480,729 shares of voting common stock, $0.0001 par value per share, and 4,745,225 shares of non-voting common stock, $0.0001 par value per share, outstanding.

19,480,729 + 4,745,225 = 24,225,954 (current outstanding)

and now here:

https://finance.yahoo.com/news/tscan-therapeutics-announces-pricing-140-043700771.html

WALTHAM, Mass., May 26, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the pricing of an underwritten public offering of 22,989,474 shares of its voting common stock at a public offering price of $2.00 per share, and pre-funded warrants to purchase up to an aggregate of 47,010,526 shares of its common stock at a price to the public of $1.9999 per pre-funded warrant, which represents the per share public offering price for the voting common stock less the $0.0001 per share exercise price for each such pre-funded warrant.

From above :

24,225,954 (current outstanding) + 22,989,474 ( proposed public offering) =
47,215,428 will be the new current outstanding,and if all pre-funded warrants are exercised that brings in an additional 47,010,526 shares for a grand total of 94,225,954 shares outstanding.